CLINICAL_TRIALS
trial_result
· 2021-07-28
Clinical Trial Update: Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease [Phase 2]
Summary
Phase 2 trial of ACE-083 in Charcot-Marie-Tooth Disease was terminated; results were posted in 2021.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Conditions: Charcot-Marie-Tooth Disease | Phase 2 | Status: TERMINATED | Results posted: 2021-07-28